M P Goetz, M Toi, J Huober, J Sohn, O Trédan, I H Park, M Campone, S-C Chen, L M Manso, S Paluch-Shimon, O C Freedman, J O'Shaughnessy, X Pivot, S M Tolaney, S Hurvitz, A Llombart-Cussac, V André, A Saha, G van Hal, A Shahir, H Iwata, S R D Johnston
BACKGROUND: In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC) with disease progression on prior endocrine therapy (ET). In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for HR+, HER2- ABC significantly improved PFS. Here, we present the prespecified final OS results for MONARCH 3. PATIENTS AND METHODS: MONARCH 3 is a randomized, double-blind, phase 3 study of abemaciclib plus NSAI (anastrozole or letrozole) versus placebo plus NSAI in postmenopausal women with HR+, HER2- ABC without prior systemic therapy in the advanced setting...
May 8, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology